Published: August 03, 2011
Research and Markets: Global Biopharma Outlook 2011: India Pharma
DUBLIN - (BUSINESS WIRE) - Research and Markets (http://www.researchandmarkets.com/research/87b099/global_biopharma_o)
has announced the addition of the "Global
Biopharma Outlook 2011: India Pharma" report to their offering.
The report discusses the major macro forces driving the Indian pharma
sector, ie:
(1) Success in Para IV litigations (2) India's pharma market growth
potential (3) Acquisitions and alliances of Indian companies
These trends are analyzed with an in-depth analysis of Indian pharma's
para IV pipeline. This report looks at how and why the domestic market
can grow and whether companies will continue to gain value through
alliances and acquisitions.
The latter part of the report discusses various Indian Pharma companies
business fundamentals with stock recommendations on the same. The
assessment of their future performance is based on the macro thesis
enumerated at the start of the report.
Companies Mentioned:
-
Sun Pharma
-
Ipca
-
Cadila Healthcare
-
Lupin
-
Biocon
-
Aurobindo Pharma
-
Dishman
-
Cipla
-
Dr Reddy's Lab
-
Piramal Healthcare
-
Ranbaxy
-
Wockhardt
Some Key Topics Covered: India Pharma: Macro View
Para IV - The New India Advantage
Table 2: Indian Cos. Presence in Para IV of Top 20 Products
Table 3: Snapshot of Indian Cos. Para IV Presence
Table 4: Important Para IV Milestones of Indian Cos.
Table 5: Comprehensive List of Para IVs of Indian Cos.
Domestic Formulations - Regulatory Scenario Guarantees Further Growth
-
Chart 1: India Market Growth Analysis
-
Strict Implementation of GMP Norms Helped Consolidation
-
Mandatory GLP Norms - Fresh Salvo
-
Table 6: Indian Cos. Continue To Invest In Sales Force Expansion
Acquisition - Can it Be another Stock Driver?
Manufacturing Alliances - Generics to Gain The Most
-
Why We Do Not Expect Pure Play Contract Manufacturers To Gain
Significantly?
-
Table 7: Manufacturing Alliances with Generic Companies
Industry Capsules
Sun Pharma
Domestic Formulations - Robust Growth Taro Business Overview
-
Current Position of Taro
-
Taro's Business - Mix of Branded and Generic Dermatology
-
Taro's Manufacturing Facilities
-
What Does Taro Mean For Sun?
Export Formulations - Leaving Protonix Behind
Launch of Effexor XR with 180-Day Exclusivity
Upcoming Para IV / Low Competition Opportunities
-
Prandin
-
Stalevo
-
Strattera
-
Gemzar
-
Taxotere
To see a full list of key topics covered and for more information visit http://www.researchandmarkets.com/research/87b099/global_biopharma_o
Research and Markets
Laura Wood, Senior Manager
U.S. Fax:
646-607-1907
Fax (outside U.S.): +353-1-481-1716
press@researchandmarkets.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
